Activation of cannabinoid 2 receptors protects against c neutrophil recruitment

FASEB Journal

24, 788-798

DOI: 10.1096/fj.09-141275

Citation Report

#	Article	IF	Citations
1	Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radical Biology and Medicine, 2010, 48, 457-467.	1.3	181
2	Intracerebral Hemorrhage Research. Acta Neurochirurgica Supplementum, 2011, , .	0.5	4
3	HIV-1 infection and alcohol abuse: Neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain, Behavior, and Immunity, 2011, 25, S61-S70.	2.0	111
4	TWEAK regulates proliferation and differentiation of adult neural progenitor cells. Molecular and Cellular Neurosciences, 2011, 46, 325-332.	1.0	20
5	Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Progress in Lipid Research, 2011, 50, 193-211.	5.3	362
6	Monocyte Chemoattractant Protein-1-Deficiency Impairs the Expression of IL-6, IL-1Î² and G-CSF after Transient Focal Ischemia in Mice. PLoS ONE, 2011, 6, e25863.	1.1	58
7	Influenza Virus Infection Aggravates Stroke Outcome. Stroke, 2011, 42, 783-791.	1.0	104
8	Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia. Current Neurovascular Research, 2011, 8, 145-152.	0.4	18
9	Chronic Î”-9-tetrahydrocannabinol Administration Increases Lymphocyte CXCR4 Expression in Rhesus Macaques. Journal of NeuroImmune Pharmacology, 2011, 6, 540-545.	2.1	15
10	Cannabinoids Inhibit Migration of Microglial-like Cells to the HIV Protein Tat. Journal of NeuroImmune Pharmacology, 2011, 6, 566-577.	2.1	39
11	CB2 cannabinoid receptor targets mitogenic Gi proteinâ€“cyclin D1 axis in osteoblasts. Journal of Bone and Mineral Research, 2011, 26, 308-316.	3.1	73
12	Pannexins in ischemia-induced neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20772-20777.	3.3	202
13	CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thrombosis and Haemostasis, 2011, 105, 409-420.	1.8	119
14	A Signaling Cascade of Nuclear Calcium-CREB-ATF3 Activated by Synaptic NMDA Receptors Defines a Gene Repression Module That Protects against Extrasynaptic NMDA Receptor-Induced Neuronal Cell Death and Ischemic Brain Damage. Journal of Neuroscience, 2011, 31, 4978-4990.	1.7	128
15	Green Tea Epigallo-Catechin-Galleate Ameliorates the Development of Obliterative Airway Disease. Experimental Lung Research, 2011, 37, 435-444.	0.5	13
16	Activation of Cannabinoid Receptor 2 Attenuates Leukocyteâ€“Endothelial Cell Interactions and Bloodâ€“Brain Barrier Dysfunction under Inflammatory Conditions. Journal of Neuroscience, 2012, 32, 4004-4016.	1.7	202
17	Immune mechanisms of stroke. Current Opinion in Neurology, 2012, 25, 334-340.	1.8	71
18	Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection. Stroke, 2012, 43, 211-219.	1.0	179

#	Article	IF	Citations
19	Visualization by mass spectrometry of 2â€dimensional changes in rat brain lipids, including N â€acylphosphatidylethanolamines, during neonatal brain ischemia. FASEB Journal, 2012, 26, 2667-2673.	0.2	53
20	Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood, 2012, 120, 3793-3802.	0.6	374
21	Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood, 2012, 120, 3741-3749.	0.6	66
22	Targeting cannabinoid receptor CB₂ in cardiovascular disorders: promises and controversies. British Journal of Pharmacology, 2012, 167, 313-323.	2.7	101
23	Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease. Journal of Neuroscience, 2012, 32, 18259-18268.	1.7	115
24	Unique Effects of Compounds Active at Both Cannabinoid and Serotonin Receptors During Stroke. Translational Stroke Research, 2012, 3, 348-356.	2.3	12
25	CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. Journal of Psychopharmacology, 2012, 26, 92-103.	2.0	158
26	Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience, 2012, 207, 307-315.	1.1	47
27	Î”⁸â€Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB₂ receptors. British Journal of Pharmacology, 2012, 165, 2450-2461.	2.7	38
28	The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. Journal of Neuroinflammation, 2012, 9, 79.	3.1	64
29	Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1796-1806.	3.3	25
30	Connexin 36 promotes cortical spreading depolarization and ischemic brain damage. Brain Research, 2012, 1479, 80-85.	1.1	12
31	Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. Neuroscience, 2012, 227, 313-326.	1.1	33
32	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2012, 55, 5391-5402.	2.9	27
33	A new cannabinoid CB₂ receptor agonist HUâ€910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. British Journal of Pharmacology, 2012, 165, 2462-2478.	2.7	90
34	Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10â^'/â^' mice by attenuating the activation of T cells and promoting their apoptosis. Toxicology and Applied Pharmacology, 2012, 258, 256-267.	1.3	106
35	Proteolytic Activity Attenuates the Response of Endothelial Cells to Fluid Shear Stress. Cellular and Molecular Bioengineering, 2012, 5, 82-91.	1.0	7
36	Activation of Cannabinoid CB2 Receptorâ€“Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury. American Journal of Pathology, 2013, 182, 928-939.	1.9	134

#	Article	IF	Citations
37	Cannabinoids Inhibit T-cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction. Journal of NeuroImmune Pharmacology, 2013, 8, 1239-1250.	2.1	44
38	Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 608-620.	2.1	191
39	Systemic immune activation shapes stroke outcome. Molecular and Cellular Neurosciences, 2013, 53, 14-25.	1.0	67
40	Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: Therapeutic time window, combination with t-PA and efficacy in aged rats. Brain Research, 2013, 1526, 84-93.	1.1	11
41	Trisubstituted Sulfonamides: A New Chemotype for Development of Potent and Selective CB₂ Receptor Inverse Agonists. ACS Medicinal Chemistry Letters, 2013, 4, 387-392.	1.3	16
42	Interleukin-17 in post-stroke neurodegeneration. Neuroscience and Biobehavioral Reviews, 2013, 37, 436-447.	2.9	73
43	Modulating the endocannabinoid system in human health and disease â€“ successes and failures. FEBS Journal, 2013, 280, 1918-1943.	2.2	315
44	N2 Neutrophils, Novel Players in Brain Inflammation After Stroke. Stroke, 2013, 44, 3498-3508.	1.0	284
45	2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. Journal of Leukocyte Biology, 2013, 93, 267-276.	1.5	34
46	Treatment with Evasin-3 Reduces Atherosclerotic Vulnerability for Ischemic Stroke, but Not Brain Injury in Mice. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 490-498.	2.4	55
47	Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury. Brain Sciences, 2013, 3, 1043-1059.	1.1	20
48	Aging aggravates ischemic stroke-induced brain damage in mice with chronic peripheral infection. Aging Cell, 2013, 12, 842-850.	3.0	35
49	Stroke: Pathophysiology and Therapy. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2013, 5, 1-91.	0.3	0
50	Mass Transfer and Computational Fluid-dynamics in Bioreactors. , 2013, , 460-486.		0
51	Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarateâ€™s protective effect in EAE. Journal of Clinical Investigation, 2014, 124, 2188-2192.	3.9	255
52	Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. Journal of the Neurological Sciences, 2014, 342, 101-106.	0.3	41
53	Cancer risks from diabetes therapies: Evaluating the evidence. , 2014, 144, 71-81.		16
54	Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREBâ€“Bcl-2 pathway after subarachnoid hemorrhage in rats. Experimental Neurology, 2014, 261, 396-403.	2.0	47

#	Article	IF	Citations
55	The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in rats. Neuroscience Letters, 2014, 569, 104-109.	1.0	15
56	What we know and do not know about the cannabinoid receptor 2 (CB2). Seminars in Immunology, 2014, 26, 369-379.	2.7	95
57	Functions of the CB1 and CB2 Receptors in Neuroprotection at the Level of the Bloodâ€“Brain Barrier. NeuroMolecular Medicine, 2014, 16, 620-642.	1.8	50
59	Cannabinoid 2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation. Clinical Hemorheology and Microcirculation, 2015, 61, 237-249.	0.9	28
60	Peripherally Restricted Cannabinoids for the Treatment of Pain. Pharmacotherapy, 2015, 35, 917-925.	1.2	21
61	Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. PLoS ONE, 2015, 10, e0141600.	1.1	7
62	Complexity of the cellâ€“cell interactions in the innate immune response after cerebral ischemia. Brain Research, 2015, 1623, 53-62.	1.1	17
64	A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10. Journal of NeuroImmune Pharmacology, 2015, 10, 318-332.	2.1	40
65	Cannabinoid CB2 receptor stimulation attenuates brain edema and neurological deficits in a germinal matrix hemorrhage rat model. Brain Research, 2015, 1602, 127-135.	1.1	18
66	Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses. Journal of NeuroImmune Pharmacology, 2015, 10, 268-280.	2.1	60
67	Cannabinoids in Experimental Stroke: A Systematic Review and Meta-Analysis. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 348-358.	2.4	71
68	Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System. Current Cardiology Reports, 2015, 17, 627.	1.3	13
69	CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery. Neuroscience Letters, 2015, 597, 19-24.	1.0	11
70	Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. Journal of Leukocyte Biology, 2015, 97, 1049-1070.	1.5	168
71	Downstream effects of endocannabinoid on blood cells: implications for health and disease. Cellular and Molecular Life Sciences, 2015, 72, 3235-3252.	2.4	10
72	The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia. Nature Communications, 2015, 6, 6340.	5.8	110
73	Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation. Trends in Molecular Medicine, 2015, 21, 245-255.	3.5	70
74	Endocannabinoids. Handbook of Experimental Pharmacology, 2015, , .	0.9	19

#	Article	IF	Citations
75	Genetic Manipulation of the Endocannabinoid System. Handbook of Experimental Pharmacology, 2015, 231, 129-183.	0.9	17
76	New horizons for newborn brain protection: enhancing endogenous neuroprotection. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F541-F552.	1.4	164
77	Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics, 2015, 12, 793-806.	2.1	108
78	Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. Acta Neuropathologica, 2015, 129, 259-277.	3.9	210
79	Immune System Involvement in the Degeneration, Neuroprotection, and Restoration after Stroke. , 0, , .		2
80	The cannabinoid 2 receptor agonist Î²-caryophyllene modulates the inflammatory reaction induced by Mycobacterium bovis BCG by inhibiting neutrophil migration. Inflammation Research, 2016, 65, 869-879.	1.6	31
81	Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, 166, 40-55.		127
82	CB2 cannabinoid receptors modulate HIF-1Î± and TIM-3 expression in a hypoxia-ischemia mouse model. European Neuropsychopharmacology, 2016, 26, 1972-1988.	0.3	23
83	Cannabinoid 2 Receptor Agonist Improves Systemic Sensitivity to Insulin in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Cellular Physiology and Biochemistry, 2016, 40, 1175-1185.	1.1	26
84	Post-ischemic treatment of WIB801C, standardized Cordyceps extract, reduces cerebral ischemic injury via inhibition of inflammatory cell migration. Journal of Ethnopharmacology, 2016, 186, 169-180.	2.0	18
85	Î²â€Caryophyllene protects inÂvitro neurovascular unit against oxygenâ€glucose deprivation and reâ€oxygenationâ€induced injury. Journal of Neurochemistry, 2016, 139, 757-768.	2.1	43
86	CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinsonâ€™s disease. Experimental and Molecular Medicine, 2016, 48, e205-e205.	3.2	103
87	Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica, 2016, 101, 566-577.	1.7	51
88	Non-Neuronal Mechanisms of Brain Damage and Repair After Stroke. Springer Series in Translational Stroke Research, 2016, , .	0.1	1
89	The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences, 2016, 73, 4449-4470.	2.4	375
90	Role of neutrophils in atherogenesis: an update. European Journal of Clinical Investigation, 2016, 46, 252-263.	1.7	32
91	Effects of cannabinoids and their receptors on viral infections. Journal of Medical Virology, 2016, 88, 1-12.	2.5	52
92	Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. Biomaterials, 2016, 81, 169-180.	5.7	69

#	Article	IF	Citations
93	Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors. Molecular Neurobiology, 2016, 53, 2312-2319.	1.9	32
94	Cannabinoids to treat spinal cord injury. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 190-199.	2.5	20
95	Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11 C]RS-016 targeting CB2 in atherosclerosis. Nuclear Medicine and Biology, 2017, 47, 31-43.	0.3	26
96	PET imaging of cannabinoid type 2 receptors with [¹¹C]A-836339 did not evidence changes following neuroinflammation in rats. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1163-1178.	2.4	31
97	The endocannabinoid system, a novel and key participant in acupunctureâ€™s multiple beneficial effects. Neuroscience and Biobehavioral Reviews, 2017, 77, 340-357.	2.9	15
98	Inhibitory effect of trans-caryophyllene (TC) on leukocyte-endothelial attachment. Toxicology and Applied Pharmacology, 2017, 329, 326-333.	1.3	22
99	Genetic neutrophil deficiency ameliorates cerebral ischemia-reperfusion injury. Experimental Neurology, 2017, 298, 104-111.	2.0	23
100	Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine. International Journal of Molecular Sciences, 2017, 18, 1617.	1.8	19
101	Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury. Frontiers in Immunology, 2017, 8, 875.	2.2	19
102	Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	24
103	Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity. Journal of Neuroinflammation, 2017, 14, 138.	3.1	72
104	Is the Cannabinoid CB 2 Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans?. Advances in Pharmacology, 2017, 80, 367-396.	1.2	9
105	AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice. Oncotarget, 2017, 8, 67837-67850.	0.8	29
106	The role of monocytosis and neutrophilia in atherosclerosis. Journal of Cellular and Molecular Medicine, 2018, 22, 1366-1382.	1.6	48
107	Upregulation of Microglial ZEB1 Ameliorates Brain Damage after Acute Ischemic Stroke. Cell Reports, 2018, 22, 3574-3586.	2.9	62
108	Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence, 2018, 9, 217-230.	1.8	54
109	Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. Prostaglandins and Other Lipid Mediators, 2018, 139, 54-62.	1.0	15
110	Targeting pain at its source in sickle cell disease. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2018, 315, R104-R112.	0.9	29

#	Article	IF	Citations
111	Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues. Antioxidants, 2018, 7, 93.	2.2	71
112	Cannabinoid Receptors as Regulators of Neutrophil Activity in Inflammatory Diseases. , 2019, , .		5
113	Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules, 2019, 24, 3709.	1.7	16
114	N2 neutrophils may participate in spontaneous recovery after transient cerebral ischemia by inhibiting ischemic neuron injury in rats. International Immunopharmacology, 2019, 77, 105970.	1.7	24
115	Role of TLR4 (Toll-Like Receptor 4) in N1/N2 Neutrophil Programming After Stroke. Stroke, 2019, 50, 2922-2932.	1.0	106
116	The protective effect of cannabinoid type 2 receptor activation on renal ischemiaâ€“reperfusion injury. Molecular and Cellular Biochemistry, 2019, 462, 123-132.	1.4	14
117	Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective. Frontiers in Pharmacology, 2019, 10, 1481.	1.6	29
118	The ameliorating effect of cannabinoid type 2 receptor activation on brain, lung, liver and heart damage in cecal ligation and puncture-induced sepsis model in rats. International Immunopharmacology, 2020, 78, 105978.	1.7	16
119	The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders. Acta Pharmacologica Sinica, 2020, 41, 1507-1518.	2.8	17
120	Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. Translational Stroke Research, 2021, 12, 550-558.	2.3	13
121	Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 588195.	1.8	7
122	Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction. CNS and Neurological Disorders - Drug Targets, 2021, 20, 963-974.	0.8	7
123	Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation. International Journal of Molecular Sciences, 2021, 22, 5431.	1.8	49
124	G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential. Molecular Neurobiology, 2021, 58, 4588-4614.	1.9	9
125	The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules, 2021, 26, 4551.	1.7	17
126	Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19. Immuno, 2021, 1, 285-304.	0.6	1
127	The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102047.	1.1	24
128	Brain Immune Interactionsâ€”Novel Emerging Options to Treat Acute Ischemic Brain Injury. Cells, 2021, 10, 2429.	1.8	15

#	Article	IF	Citations
129	Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases. European Journal of Pharmacology, 2021, 909, 174398.	1.7	3
130	Neutrophil Depletion Diminishes Monocyte Infiltration and Improves Functional Outcome After Experimental Intracerebral Hemorrhage. Acta Neurochirurgica Supplementum, 2011, 111, 173-178.	0.5	66
131	Pseudoginsenoside-F11 ameliorates ischemic neuron injury by regulating the polarization of neutrophils and macrophages in vitro. International Immunopharmacology, 2020, 85, 106564.	1.7	9
132	Cannabinoid Receptor 2 Signaling Does Not Modulate Atherogenesis in Mice. PLoS ONE, 2011, 6, e19405.	1.1	21
133	Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimerâ€™s Disease and Less Well-Known Diseases. Current Medicinal Chemistry, 2019, 26, 3300-3340.	1.2	13
134	<i>Helicobacter</i> infection decreases basal colon inflammation, but increases disease activity in experimental IBD. Open Journal of Gastroenterology, 2013, 03, 177-189.	0.1	5
135	Role of aryl hydrocarbon receptor in mesenchymal stromal cell activation: A minireview. World Journal of Stem Cells, 2017, 9, 152-158.	1.3	6
137	Cannabinoids in the Brain: Their Metabolism, Roles, and Involvement in Neurological Disorders. , 2011, , 133-157.		0
138	Roles of Neutrophils in Stroke. Springer Series in Translational Stroke Research, 2016, , 273-301.	0.1	0
139	NOX2 is involved in CB2-mediated protection against lung ischemia-reperfusion injury in mice. International Journal of Clinical and Experimental Pathology, 2020, 13, 277-285.	0.5	4
140	A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo. Frontiers in Pharmacology, 2021, 12, 804950.	1.6	3
141	â€œThe Two Sides of the Same Coinâ€â€”Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained. Pharmaceutics, 2022, 14, 389.	2.0	16
144	Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis. Pharmaceutics, 2022, 14, 936.	2.0	4
145	Effect of Different Psychoactive Substances on Hematological Parameters of Dependents in TÃ¼rkiye. The Journal of Pediatric Academy, 2022, 3, 191-196.	0.1	0
146	Neuroprotection by the cannabidiol aminoquinone VCE-004.8 in experimental ischemic stroke in mice. Neurochemistry International, 2023, 165, 105508.	1.9	1
148	Targeting the CB (2) receptor to delay progression of cardiovascular diseases. , 2023, , 171-182.		0